Healthcare provider profile · identity verified

Patrick S Callender, DO

Internal Medicine · COLUMBUS, OH · NPI 1922006675

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	561	183
Amlodipine Besylate	Amlodipine Besylate	347	113
Gabapentin	Gabapentin	318	87
Albuterol Sulfate Hfa	Albuterol Sulfate	261	90
Lisinopril	Lisinopril	237	86
Losartan Potassium	Losartan Potassium	218	75
Tizanidine Hcl	Tizanidine Hcl	181	59
Metformin Hcl	Metformin Hcl	170	57
Hydrochlorothiazide	Hydrochlorothiazide	161	65
Pantoprazole Sodium	Pantoprazole Sodium	160	64
Omeprazole	Omeprazole	150	54
Prednisone	Prednisone	144	86
Levothyroxine Sodium	Levothyroxine Sodium	143	43
Furosemide	Furosemide	139	55
Baclofen	Baclofen	137	51
Trazodone Hcl	Trazodone Hcl	133	46
Carvedilol	Carvedilol	123	42
Potassium Chloride	Potassium Chloride	119	49
Metoprolol Succinate	Metoprolol Succinate	115	46
Tramadol Hcl	Tramadol Hcl	104	25
Tamsulosin Hcl	Tamsulosin Hcl	98	36
Fluticasone Propionate	Fluticasone Propionate	97	42
Glipizide	Glipizide	92	29
Famotidine	Famotidine	85	23
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	82	61
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	79	32
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	77	24
Hydralazine Hcl	Hydralazine Hcl	73	24
Spironolactone	Spironolactone	73	23
Diclofenac Sodium	Diclofenac Sodium	72	32
Metoprolol Tartrate	Metoprolol Tartrate	71	29
Hydroxyzine Hcl	Hydroxyzine Hcl	69	35
Rosuvastatin Calcium	Rosuvastatin Calcium	69	28
Montelukast Sodium	Montelukast Sodium	66	27
Meloxicam	Meloxicam	65	26
Eliquis	Apixaban	64	16
Azithromycin	Azithromycin	62	48
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	62	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	22
Citalopram Hbr	Citalopram Hydrobromide	54	20
Sertraline Hcl	Sertraline Hcl	52	25
Simvastatin	Simvastatin	51	18
Duloxetine Hcl	Duloxetine Hcl	50	19
Triamcinolone Acetonide	Triamcinolone Acetonide	49	33
Ibuprofen	Ibuprofen	48	19
Metformin Hcl Er	Metformin Hcl	47	19
Ondansetron Odt	Ondansetron	47	22
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	47	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	46	15
Alendronate Sodium	Alendronate Sodium	44	20
Alprazolam	Alprazolam	44	suppressed
Clopidogrel	Clopidogrel Bisulfate	44	19
Clonidine Hcl	Clonidine Hcl	43	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	43	36
Meclizine Hcl	Meclizine Hcl	42	22
Oxybutynin Chloride	Oxybutynin Chloride	42	15
Naproxen	Naproxen	41	15
Allopurinol	Allopurinol	39	16
Pravastatin Sodium	Pravastatin Sodium	37	15
Novolog Flexpen	Insulin Aspart	36	11
Xarelto	Rivaroxaban	36	suppressed
Januvia	Sitagliptin Phosphate	35	suppressed
Ozempic	Semaglutide	35	11
Pregabalin	Pregabalin	35	13
Valsartan	Valsartan	35	suppressed
Spiriva Respimat	Tiotropium Bromide	34	suppressed
Atenolol	Atenolol	33	suppressed
Donepezil Hcl	Donepezil Hcl	32	20
Oxybutynin Chloride Er	Oxybutynin Chloride	31	13
Jardiance	Empagliflozin	30	11
Pioglitazone Hcl	Pioglitazone Hcl	30	suppressed
Promethazine Hcl	Promethazine Hcl	30	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Lidocaine	Lidocaine	28	suppressed
Mirtazapine	Mirtazapine	27	15
Topiramate	Topiramate	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	25	11
Warfarin Sodium	Warfarin Sodium	24	suppressed
Glimepiride	Glimepiride	23	suppressed
Nifedipine Er	Nifedipine	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	22	suppressed
Finasteride	Finasteride	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	22	suppressed
Acarbose	Acarbose	21	suppressed
Methocarbamol	Methocarbamol	21	suppressed
Torsemide	Torsemide	21	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	18	suppressed
Ammonium Lactate	Ammonium Lactate	17	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	16	suppressed
Mometasone Furoate	Mometasone Furoate	16	suppressed
Myrbetriq	Mirabegron	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Theophylline Er	Theophylline Anhydrous	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Ibu	Ibuprofen	13	suppressed
Nitroglycerin	Nitroglycerin	13	11
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	11
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Nyamyc	Nystatin	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error